DOI: 10.4244/EIJ-D-17-00457L

Concerns about left atrial appendage occlusion

Claudia Stöllberger1*, MD; Birke Schneider2, MD

We read with great interest the article by Korsholm et al about transcatheter left atrial appendage occlusion (LAAO) in patients with atrial fibrillation (AF) and a high bleeding risk using aspirin (ASA) alone for post-implant antithrombotic therapy1. The authors conclude from their findings that LAAO with the AMPLATZER™ Cardiac Plug (ACP) or Amulet™ device (both St. Jude Medical, St. Paul, MN, USA) was safely performed with ASA monotherapy after implantation without an increased risk of device-related thrombosis or stroke. We have the following questions and concerns.

How do the authors explain the high mortality of the patients included in their study? Mortality is much higher than in other studies reporting on LAAO (Table 1) despite similar CHA2DS2-VASc scores2-4. It would be of great interest to know how long the estimated life expectancy was when the patients underwent LAAO.

Although the authors indicate that “none of the 20 deaths was procedure- or device-related”, it is important to know the exact cause of death. The left atrial appendage (LAA) is a structure for release of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). In normal human hearts, ANP concentration is 40-fold higher in the LAA than in the rest of the atrial free wall and in the ventricular endocardium. Since natriuretic peptides play an important role in fluid regulation, volume homeostasis, and thirst perception, LAA elimination may impede physiologic regulation of heart failure and thirst perception. A decrease of ANP- and BNP-serum levels after LAAO has been described in small cohorts5,6. Furthermore, dysregulation of ANP and BNP has been associated with obesity, glucose intolerance, type 2 diabetes mellitus, and essential hypertension. Moreover, natriuretic peptides have been implicated in protection against atherosclerosis, thrombosis, and myocardial ischaemia7. Thus, some of these secondary effects might possibly explain the high mortality.

Although follow-up investigations by transoesophageal echocardiography and CT had been carried out in the majority of the study patients, astonishingly no information is given about the rate of leaks between the LAA wall and the devices. The LAA myocardium has a higher distensibility than the left atrial myocardium. Progressive dilation of the LAA is observed in AF and thereby leakage of an initially completely closed LAA may occur8. After surgical LAAO, leaks are associated with thromboembolic events9. Since it is unknown how many “late leaks” develop after interventional LAAO and whether they are clinically relevant, imaging studies later than 12 months post implantation should be implemented.

Conflict of interest statement

The authors have no conflicts of interest to declare.


References

Volume 13 Number 8
Oct 20, 2017
Volume 13 Number 8
View full issue


Key metrics

Suggested by Cory

10.4244/EIJ-D-17-00457R Oct 20, 2017
Left atrial appendage occlusion is promising, not concerning
free

Editorial

10.4244/EIJ-E-24-00001 Mar 4, 2024
Navigating the complexities of antithrombotic therapy after LAAO
Alkhouli M
free

10.4244/EIJV11I14A307 Apr 8, 2016
Percutaneous left atrial appendage occlusion in 2016
Tzikas A et al
free

10.4244/EIJV16I9A129 Oct 9, 2020
Left atrial appendage closure – ready for widespread clinical use?
Widimský P and Osmancik P
free

State-of-the-art

10.4244/EIJ-D-22-00627 Feb 6, 2023
Left atrial appendage occlusion
Holmes D et al
free

Editorial

10.4244/EIJ-E-24-00041 Aug 19, 2024
Left atrial appendage occlusion needs lifetime management not lifetime medications
Gafoor S and Panaich S
free
Trending articles
172.65

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
95.95

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
76.3

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
63

Image – Interventional flashlight

10.4244/EIJ-D-22-00074 Jun 3, 2022
Transcatheter aortic valve repair for aortic regurgitation with the Cusper device
Feld Y et al
free
58.2

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
49.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
49.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
31.1

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
30.4

Clinical Research

10.4244/EIJ-D-21-00363 Jan 28, 2022
Membranous septum morphology and risk of conduction abnormalities after transcatheter aortic valve implantation
Jørgensen T et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved